Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
108 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37060187/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
RILZABRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5270 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37060187/ |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
RILZABRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
336 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37060187/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
RILZABRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1830 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37060187/ |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
RILZABRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37060187/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
RILZABRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37060187/ |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
RILZABRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 22:17:23 GMT 2025
by
admin
on
Mon Mar 31 22:17:23 GMT 2025
|
| Record UNII |
NWN58M4F5T
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
582517
Created by
admin on Mon Mar 31 22:17:23 GMT 2025 , Edited by admin on Mon Mar 31 22:17:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
605717
Created by
admin on Mon Mar 31 22:17:23 GMT 2025 , Edited by admin on Mon Mar 31 22:17:23 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000177401
Created by
admin on Mon Mar 31 22:17:23 GMT 2025 , Edited by admin on Mon Mar 31 22:17:23 GMT 2025
|
PRIMARY | |||
|
10966
Created by
admin on Mon Mar 31 22:17:23 GMT 2025 , Edited by admin on Mon Mar 31 22:17:23 GMT 2025
|
PRIMARY | |||
|
1575591-66-0
Created by
admin on Mon Mar 31 22:17:23 GMT 2025 , Edited by admin on Mon Mar 31 22:17:23 GMT 2025
|
PRIMARY | |||
|
HI-144
Created by
admin on Mon Mar 31 22:17:23 GMT 2025 , Edited by admin on Mon Mar 31 22:17:23 GMT 2025
|
PRIMARY | |||
|
C174769
Created by
admin on Mon Mar 31 22:17:23 GMT 2025 , Edited by admin on Mon Mar 31 22:17:23 GMT 2025
|
PRIMARY | |||
|
NWN58M4F5T
Created by
admin on Mon Mar 31 22:17:23 GMT 2025 , Edited by admin on Mon Mar 31 22:17:23 GMT 2025
|
PRIMARY |
All of the following components must be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
PRN-1008 is a covalent, but reversible BTK inhibitor
BINDING
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
